ADAP
Price
$0.18
Change
+$0.02 (+12.50%)
Updated
Oct 15, 11:16 AM (EDT)
Capitalization
42.73M
20 days until earnings call
Intraday Buy/Sell Signals
ETNB
Price
$14.80
Change
+$0.02 (+0.14%)
Updated
Oct 15, 11:15 AM (EDT)
Capitalization
2.2B
21 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ADAP vs ETNB

Header iconADAP vs ETNB Comparison
Open Charts ADAP vs ETNBBanner chart's image
Adaptimmune Therapeutics
Price$0.18
Change+$0.02 (+12.50%)
Volume$144.9K
Capitalization42.73M
89bio
Price$14.80
Change+$0.02 (+0.14%)
Volume$1.49K
Capitalization2.2B
ADAP vs ETNB Comparison Chart in %
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ETNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. ETNB commentary
Oct 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and ETNB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 16, 2025
Stock price -- (ADAP: $0.16 vs. ETNB: $14.80)
Brand notoriety: ADAP and ETNB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 42% vs. ETNB: 48%
Market capitalization -- ADAP: $42.73M vs. ETNB: $2.2B
ADAP [@Biotechnology] is valued at $42.73M. ETNB’s [@Biotechnology] market capitalization is $2.2B. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileETNB’s FA Score has 1 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • ETNB’s FA Score: 1 green, 4 red.
According to our system of comparison, both ADAP and ETNB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 6 TA indicator(s) are bullish while ETNB’s TA Score has 4 bullish TA indicator(s).

  • ADAP’s TA Score: 6 bullish, 3 bearish.
  • ETNB’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ADAP is a better buy in the short-term than ETNB.

Price Growth

ADAP (@Biotechnology) experienced а +16.31% price change this week, while ETNB (@Biotechnology) price change was -0.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.44%. For the same industry, the average monthly price growth was +17.42%, and the average quarterly price growth was +81.94%.

Reported Earning Dates

ADAP is expected to report earnings on Nov 05, 2025.

ETNB is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ETNB($2.2B) has a higher market cap than ADAP($42.7M). ETNB YTD gains are higher at: 89.258 vs. ADAP (-70.076). ADAP has higher annual earnings (EBITDA): -149.75M vs. ETNB (-442.86M). ETNB has more cash in the bank: 561M vs. ADAP (26.1M). ETNB has less debt than ADAP: ETNB (37.6M) vs ADAP (48.7M). ADAP has higher revenues than ETNB: ADAP (65.1M) vs ETNB (0).
ADAPETNBADAP / ETNB
Capitalization42.7M2.2B2%
EBITDA-149.75M-442.86M34%
Gain YTD-70.07689.258-79%
P/E RatioN/AN/A-
Revenue65.1M0-
Total Cash26.1M561M5%
Total Debt48.7M37.6M130%
FUNDAMENTALS RATINGS
ADAP vs ETNB: Fundamental Ratings
ADAP
ETNB
OUTLOOK RATING
1..100
2122
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
3636
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ETNB's Valuation (32) in the null industry is in the same range as ADAP (39) in the Biotechnology industry. This means that ETNB’s stock grew similarly to ADAP’s over the last 12 months.

ETNB's Profit vs Risk Rating (100) in the null industry is in the same range as ADAP (100) in the Biotechnology industry. This means that ETNB’s stock grew similarly to ADAP’s over the last 12 months.

ETNB's SMR Rating (99) in the null industry is in the same range as ADAP (100) in the Biotechnology industry. This means that ETNB’s stock grew similarly to ADAP’s over the last 12 months.

ETNB's Price Growth Rating (36) in the null industry is in the same range as ADAP (36) in the Biotechnology industry. This means that ETNB’s stock grew similarly to ADAP’s over the last 12 months.

ETNB's P/E Growth Rating (100) in the null industry is in the same range as ADAP (100) in the Biotechnology industry. This means that ETNB’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPETNB
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
78%
Bullish Trend 11 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 9 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ETNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSSCX15.14N/A
N/A
Goldman Sachs Small Cap Value C
TIOPX17.36N/A
N/A
Nuveen International Opps Prem
ADOIX19.60N/A
N/A
AXS Dynamic Opportunity I
MACEX15.99N/A
N/A
ClearBridge Emerging Markets A
ACIHX70.25N/A
N/A
American Century Growth G

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with AKBA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
-10.49%
AKBA - ADAP
41%
Loosely correlated
+0.36%
ORMP - ADAP
36%
Loosely correlated
-2.07%
ETNB - ADAP
34%
Loosely correlated
N/A
CSLLY - ADAP
32%
Poorly correlated
+1.01%
AXON - ADAP
31%
Poorly correlated
-0.75%
More

ETNB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ETNB has been loosely correlated with AKRO. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ETNB jumps, then AKRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ETNB
1D Price
Change %
ETNB100%
N/A
AKRO - ETNB
52%
Loosely correlated
+0.28%
IDYA - ETNB
49%
Loosely correlated
+1.12%
BEAM - ETNB
47%
Loosely correlated
+0.12%
NTLA - ETNB
46%
Loosely correlated
+0.57%
VRDN - ETNB
45%
Loosely correlated
-2.81%
More